News >

Time-Limited Therapy With Drug Cessation Feasible in CLL

Kristi Rosa
Published: Friday, Jan 04, 2019

John F. Seymour, MBBS, PhD

John F. Seymour, MBBS, PhD
Targeted agents are here to stay when it comes to chronic lymphocytic leukemia (CLL), said John F. Seymour, MBBS, PhD. Additionally, combination therapies, as demonstrated by the phase III MURANO trial, can achieve deeper responses and enable the use of time-limited therapy in this patient population.

, Seymour discussed the clinical implications of the MURANO trial and highlighted the feasibility for time-limited therapy and its benefits for patients with CLL.

OncLive: How was the MURANO trial designed?

Seymour: MURANO [was a trial with] a superiority design. It was randomized [trial that tested the venetoclax combination] head-to-head in a 1:1 fashion against BR. Initially, there was no crossover built into the study, so patients who progressed on either arm then received treatment at physician’s discretion.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication